Physician profile
David A Johnston
NPI 1750674800
$9,363.97
in general payments reported to CMS, 2019-2025
41 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $900 · 2021: $1,180 · 2022: $1,367 · 2023: $1,890 · 2024: $1,454 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,345.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,108.01 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,002.89 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $851.75 | 2019-2025 | Breztri, Farxiga, Nexium |
| Glaxosmithkline, LLC. | $774.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $650.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $587.74 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $323.67 | 2019-2025 | |
| Allergan, INC. | $231.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.74 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $202.23 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.18 | 2019-2022 | |
| Exact Sciences Corporation | $164.59 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $162.72 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $155.54 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $124.81 | 2023-2025 | Gvoke Hypopen, Keveyis |
| Astellas Pharma US INC | $119.25 | 2020-2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $116.62 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $107.08 | 2020-2024 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $100.88 | 2023-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $100.57 | 2019-2025 | Trintellix |
| Genzyme Corporation | $85.00 | 2019 | |
| Mylan Specialty L.P. | $82.78 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $74.40 | 2022-2025 | Quviviq, Quviviq |
| Corcept Therapeutics | $64.90 | 2024 | Korlym |
| Viatris Specialty LLC | $51.63 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.24 | 2023-2025 | Caplyta |
| Abbott Laboratories | $41.26 | 2019-2022 | |
| Eisai INC. | $38.25 | 2020-2021 | |
| Verona Pharma, INC. | $34.38 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $29.11 | 2024 | Fanapt |
| Inari Medical, INC. | $26.86 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $25.87 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $25.57 | 2020-2024 | Zoryve |
| Genentech USA, INC. | $21.16 | 2020 | |
| Ironwood Pharmaceuticals, INC | $20.85 | 2021 | |
| Ardelyx, INC. | $17.52 | 2025 | Ibsrela |
| Sunovion Pharmaceuticals INC. | $15.46 | 2020 | |
| Sanofi Pasteur INC. | $15.03 | 2023 | |
| Amarin Pharma, INC. | $13.45 | 2020 | |
| Organon LLC | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.